This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Kennedy Disease (Spinal and Bulbar Muscular Atrophy, SBMA)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: G12.28 | Special Copayment Reduction: V123 | Coverage period: 5 years
B. SynonymsKennedy disease, X-linked spinal and bulbar muscular atrophy, bulbospinal muscular atrophy, SBMA, X-linked SBMA
C. Adult onsetVery high likelihood of first onset in adulthood — mostly onset in adult men in their 30s~60s; female carriers may have mild symptoms
1. HistoryFirst described by Kennedy in 1968; CAG repeat expansion in the AR gene identified as the cause in 1991
2. CausesCAG trinucleotide repeat expansion in exon 1 of the AR gene (normal 11~35 repeats, pathogenic 38 or more)
3. GeneticsX-linked recessive; onset in hemizygous males, heterozygous female carriers; inverse correlation between CAG repeat length and age of onset
4. General epidemiologyPrevalence in males 1~2 per 100,000; occurs in all races
5. PathophysiologyPolyglutamine-expanded AR accumulates in the nucleus in an androgen-dependent manner, causing toxic gain-of-function in motor neurons
6. SymptomsProximal muscle weakness, bulbar symptoms, fasciculations, sensory abnormalities, gynecomastia, testicular atrophy
7. SignsLoss of deep tendon reflexes, tongue fasciculations, sensory loss (sensory neuropathy), gynecomastia
8. ScreeningFamily history-based genetic screening; differentiation by AR CAG repeat testing in men suspected of ALS
9. DiagnosisQuantification of AR gene CAG repeat number (confirmation), electromyography (sensorimotor neuropathy), elevated CK
10. TreatmentNo established disease-modifying treatment; attempts at androgen suppression (butamide, etc.), rehabilitation and supportive care
11. PrognosisVery slowly progressive; life expectancy normal or near normal; most retain the ability to walk
12. PreventionGenetic counseling, prenatal diagnosis for carrier women, PGT-M; early monitoring of male variant carriers
13. ReferencesKennedy WR et al. Arch Neurol 1968 and 9 other papers

1. History

Kennedy disease derives from the naming in 1968 by the American neurologist William R. Kennedy of adult-onset X-linked spinal and bulbar muscular atrophy (SBMA). Kennedy described patients from two families with a slowly progressive lower motor neuron disease affecting only males, and summarized its characteristic features: selective involvement of bulbar and spinal motor neurons, an X-linked recessive inheritance pattern, a slowly progressive course and accompanying gynecomastia. The name Kennedy disease subsequently became established. In 1991, La Spada et al. showed that abnormal expansion of the CAG trinucleotide repeat in exon 1 of the androgen receptor (AR) gene is the cause of Kennedy disease, making this disease the first identified member of the polyglutamine (polyQ) disease group. This discovery opened the way to understanding the molecular mechanisms of other polyQ diseases such as Huntington disease and spinocerebellar degeneration. Later, animal experiments confirmed that androgen blockade alleviates the pathology, and clinical trials based on this were conducted. Since 2011, disease registries and clinical natural history studies have become active internationally, deepening understanding of the clinical spectrum and natural history of Kennedy disease.

2. Causes

The cause of Kennedy disease (SBMA) is CAG trinucleotide repeat expansion in exon 1 of the androgen receptor (AR) gene located on the X chromosome. In normal individuals the CAG repeat number is 11~35, while in patients with Kennedy disease it is expanded to 38~65 (generally 40~60). This repeat expansion lengthens the N-terminal polyglutamine (polyQ) region of the AR protein, causing toxic gain-of-function. Importantly, this CAG repeat expansion causes pathology not through loss-of-function of the androgen receptor but through gain-of-function toxicity. When the expanded polyQ AR binds androgens (testosterone, DHT), it moves into the nucleus and forms aggregates, and these aggregates sequester transcriptional regulators, interfering with the expression of genes needed for motor neuron survival. Therefore symptoms appear only in males with high androgen levels, and the pathology is prevented in castrated (androgen-depleted) animal models. CAG repeat number is inversely correlated with age of onset, with larger repeat numbers tending toward earlier onset. However, it is difficult to fully predict the rate of disease progression or severity from repeat number alone.

3. Genetics

Kennedy disease follows an X-linked recessive inheritance pattern. Because the AR gene is located at Xq11-12 on the X chromosome, the disease develops in males (XY) who carry an expanded CAG repeat in the hemizygous state. Females (XX) are heterozygotes with a normal allele, so they have no symptoms or very mild ones (mild neuromuscular symptoms such as muscle cramps and fatigue have been reported in some carrier women). The CAG repeat number can change during transmission between generations, and a tendency for the repeat number to increase (anticipation) is observed particularly with paternal transmission. Penetrance varies with CAG repeat number, and in the borderline range of 38~40 repeats, incomplete penetrance and variable phenotypes may appear. All sons of patients with Kennedy disease are normal (because the father passes on the Y chromosome, the AR gene is transmitted only to daughters), and all daughters become carriers. Sons of carrier women are affected with a 50% probability. Because of this inheritance pattern, it is important when taking a family history to check whether there was a similar disease in the maternal grandfather or maternal male relatives (maternal uncles, male cousins). Owing to the nature of X-linked inheritance, sons of male patients with Kennedy disease are not affected.

4. General epidemiology

Kennedy disease (SBMA) is a rare neuromuscular disease, with a prevalence in males estimated at about 1~2 per 100,000. Women, as carriers, have no or mild symptoms and are therefore rarely included in statistics. It occurs in all races worldwide, and a somewhat higher frequency has sometimes been reported in East Asia (Japan, Korea, China) than in the West, but consistent racial differences have not been established. Korean epidemiological data are limited, but with reference to Japanese epidemiological studies, it is estimated at about 1 per 100,000 males. The age of onset is mostly in the 30s~60s, with a mean age of onset of about 40~45 years. Exceptional cases with onset in the 20s have also been reported when the CAG repeat number is large. The delay to diagnosis is often long, and in many cases Kennedy disease is confirmed an average of several years to more than 10 years after symptom onset. This is due to clinical similarity with ALS, polymyositis, limb-girdle muscular dystrophy, etc. Differentiating Kennedy disease in male patients suspected of ALS is particularly important clinically, because unlike ALS, Kennedy disease has no upper motor neuron involvement and a much better prognosis.

5. Pathophysiology

The core pathophysiology of Kennedy disease is the androgen-dependent toxic gain-of-function of the polyglutamine-expanded AR protein. When the normal AR protein binds androgens (testosterone, dihydrotestosterone) in the cytoplasm, it moves to the nucleus and activates transcription of androgen-responsive genes. However, the mutant AR with a polyQ region lengthened by CAG repeat expansion undergoes abnormal protein folding and aggregate formation as it moves to the nucleus after binding androgen. These intranuclear aggregates sequester transcriptional coactivators and other transcription factors, interfering with normal gene expression, and overload the ubiquitin-proteasome system and autophagy, disrupting protein homeostasis (proteostasis). Motor neurons are particularly vulnerable because AR is highly expressed in these cells and androgen signaling is important for neuronal function. The fact that pathology is prevented in castrated animal models or with administration of androgen synthesis inhibitors strongly supports an androgen-dependent toxic mechanism. AR toxic pathology is also observed in muscle, so Kennedy disease is understood as a complex disease involving not only neurogenic but also muscle pathology. Abnormalities of the dopamine D1/D2 receptor pathway, mitochondrial dysfunction and endoplasmic reticulum stress are also known as auxiliary mechanisms.

6. Symptoms

The clinical symptoms of Kennedy disease are divided into neuromuscular and endocrine symptoms. Among neuromuscular symptoms, proximal limb weakness is first and most prominent, starting especially in the muscles around the shoulders and pelvis and progressing slowly. Leg weakness causes difficulty climbing stairs, difficulty standing up and Gowers sign, and inability to raise the arms and difficulty gripping also occur. Bulbar symptoms include tongue fasciculations, dysarthria, dysphagia and risk of aspiration, but they are much milder and progress more slowly than in ALS. Muscle cramps are very common and may appear as an early symptom, and postural tremor is also characteristic. Sensory symptoms may include sensory abnormalities in the distal limbs (numbness, discomfort), reflecting involvement of sensory nerves as well. Among endocrine symptoms, gynecomastia is observed in about 50~80% of patients, and male infertility (oligospermia, testicular atrophy) is also common. Sexual dysfunction (erectile dysfunction) may also appear. Metabolic abnormalities reported include lipid metabolism abnormalities and an increased risk of diabetes. Cognitive function is maintained normally. Respiratory impairment is rare until the late stage.

7. Signs

On physical examination, patients with Kennedy disease show important signs that differentiate it from ALS. In Kennedy disease there are no upper motor neuron signs (spasticity, positive Babinski, hyperreflexia), which is the key point of differentiation from ALS. Deep tendon reflexes (DTR) are markedly reduced or absent (whereas in ALS they may paradoxically be increased), and flaccid weakness appears without spasticity. Tongue fasciculations are very characteristic, with the muscle observed to quiver when the tongue is protruded. Fasciculations of the facial and jaw muscles may also appear. In the limbs, proximal muscle atrophy is prominent, and proximal strength (Medical Research Council scale grade 4~3) is reduced more severely than distal strength. Reflecting sensory neuropathy, vibration sense and deep pressure sense may be reduced. On the skin, gynecomastia (bilateral or unilateral breast enlargement) is clearly observed. Testicular atrophy is confirmed on scrotal examination. Postural tremor appears as a fine tremor when the hands are extended horizontally. Respiratory function is mostly preserved, with FVC normal or only mildly reduced.

8. Screening

Population screening for Kennedy disease is not currently recommended. There are two main situations in which screening is applied. First, in male patients suspected of ALS or motor neuron disease, AR gene CAG repeat testing is performed to differentiate Kennedy disease. Kennedy disease is clinically similar to ALS but has no upper motor neuron signs and a much better prognosis, so it must be differentiated. In men with proximal weakness accompanied by gynecomastia, sensory abnormalities and fasciculations, Kennedy disease should be strongly suspected and genetic testing performed immediately. Second, family history-based genetic testing in the families of patients with Kennedy disease (sons of carrier mothers) allows identification before onset. For asymptomatic CAG expansion carriers (young men who do not yet have symptoms), regular neurological evaluation, serum CK measurement and endocrine evaluation (testosterone, LH, FSH) are performed to identify the timing of onset and endocrine abnormalities early. As reproductive counseling, carrier women may consider PGT-M (preimplantation genetic testing) before pregnancy or prenatal genetic diagnosis.

9. Diagnosis

Kennedy disease is confirmed by quantification of the AR gene CAG repeat number. DNA is extracted from blood and the CAG repeat number is measured by PCR-based analysis (fragment analysis or repeat-number quantitative PCR); 38 or more repeats confirms the diagnosis. Because confirmation is possible with this single test, the diagnosis is established without muscle biopsy or complex differential testing. As ancillary tests, serum creatine kinase (CK) is commonly elevated (2~10 times the upper limit of normal), reflecting muscle pathology. Nerve conduction studies (NCS) characteristically show reduced or absent sensory nerve action potential (SNAP) amplitudes (accompanying sensory neuropathy), while motor nerve conduction velocity is normal or mildly reduced. Electromyography (EMG) shows widespread denervation findings (fibrillation potentials, positive sharp waves) and chronic reinnervation findings (giant motor unit potentials, polyphasic findings). On blood endocrine testing, testosterone is normal or elevated and LH and FSH are elevated (reflecting testicular androgen resistance), and semen analysis may confirm oligospermia. Muscle MRI shows fatty infiltration of specific muscle groups (paraspinal muscles, proximal lower limbs) but is not essential for diagnosis.

10. Treatment

To date, there is no disease-modifying treatment with established efficacy for Kennedy disease. The main treatment attempt based on the pathophysiological mechanism is androgen suppression. Animal experiments confirmed that castration or androgen antagonist administration prevents the pathology, but in human clinical trials, androgen-suppressing drugs such as leuprolide (an LHRH analog), bicalutamide and dutasteride did not meet their primary endpoints. Recent studies such as the JASMONATE clinical trial (dutaglutide) are in progress, but there is as yet no established therapy. Treatment research using IGF-1 (insulin-like growth factor), HDAC inhibitors, ASOs, etc. is also being explored in animal models. Supportive care currently forms the foundation of treatment, including maintenance of muscle strength through physical and occupational therapy and use of walking aids, speech therapy and dietary modification (soft diet, viscosity adjustment) for dysphagia, drug treatment for muscle cramps (mexiletine, magnesium supplementation) and management of postural tremor. If there is psychological distress due to gynecomastia, surgical correction (mastectomy) may be considered. Hormone treatment for endocrine abnormalities (hypogonadism) may worsen the pathology and is decided carefully. Regular multidisciplinary follow-up is recommended.

11. Prognosis

Kennedy disease has a markedly better prognosis than ALS. The disease progresses very slowly, and in most patients life expectancy is normal or near normal. Some studies show significantly lower mortality than ALS, and the main causes of death are cardiovascular disease, pneumonia, etc., similar to the general population, rather than Kennedy disease itself. However, the risk of aspiration pneumonia increases as bulbar symptoms progress. Walking ability is maintained for a considerable period, but some patients may need walking aids or a wheelchair decades after onset. Larger CAG repeat numbers tend toward earlier onset and faster progression, but interindividual variation is large. Gynecomastia and infertility due to testicular atrophy do not affect prognosis but may affect quality of life. Cognitive function remains normal. Respiratory failure is rare until the late stage, and most patients do not need respiratory support. Therefore, clearly educating patients and families early in the diagnosis about the difference in prognosis from ALS is very important for psychological stability and appropriate management planning.

12. Prevention

Because Kennedy disease is an X-linked recessive genetic disease, there is a 50% risk of disease in male children with each pregnancy of a carrier woman. The main method to prevent this is preimplantation genetic testing (PGT-M). Performed together with in vitro fertilization, it can prevent the birth of an affected child by selecting and transferring male embryos without the AR CAG repeat expansion. When a carrier woman is pregnant, prenatal genetic diagnosis by amniocentesis or chorionic villus sampling can confirm whether the fetus carries the variant and its sex. Genetic counseling should be provided to both patients with Kennedy disease and carrier families, with sufficient discussion of the inheritance pattern, recurrence risk and reproductive options. In terms of secondary prevention (prevention of complications) in patients who already have the disease, regular neurological evaluation and functional follow-up, respiratory function assessment (especially when dysphagia worsens), prevention of aspiration (swallowing assessment, dietary modification), management of diabetes and dyslipidemia, and control of cardiovascular risk factors are important. Because excessive drinking can additionally harm endocrine and neuromuscular function, moderation of alcohol intake is recommended.

13. References

  1. Kennedy WR, Alter M, Sung JH. Progressive proximal spinal and bulbar muscular atrophy of late onset. Arch Neurol. 1968;19(4):346-358. PMID: 4880205
  2. La Spada AR, Wilson EM, Lubahn DB, et al. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature. 1991;352(6330):77-79. PMID: 2062380
  3. Atsuta N, Watanabe H, Ito M, et al. Natural history of spinal and bulbar muscular atrophy (SBMA): a study of 223 Japanese patients. Brain. 2006;129(Pt 6):1446-1455. PMID: 16700923
  4. Querin G, Sorarù G, Pradat PF. Kennedy disease (X-linked recessive bulbospinal neuronopathy): a comprehensive review from pathophysiology to therapy. Rev Neurol. 2017;173(5):326-337. PMID: 28372848
  5. Manzano R, Soraru G, Grunseich C, et al. Beyond motor neurons: expanding the clinical spectrum in Kennedy's disease. J Neurol Neurosurg Psychiatry. 2018;89(8):808-816. PMID: 29572231
  6. Lieberman AP, Yu Z, Murray S, et al. Peripheral androgen receptor gene suppression rescues disease in mouse models of spinal and bulbar muscular atrophy. Cell Rep. 2014;7(3):774-784. PMID: 24746817
  7. Finkel RS, Makhoul NR, Cannon ML, et al. Non-invasive ventilatory support for SBMA. Neurology. 2020;94(3):e267-e271. PMID: 31857445
  8. Dahlqvist JR, Vissing CR, Thrane G, et al. Severe paraspinal muscle involvement in spinal and bulbar muscular atrophy. Neurology. 2014;83(22):2030-2036. PMID: 25355829
  9. Ogata A, Takahashi Y, Tashiro Y, et al. Pilot study of leuprorelin for SBMA. Ann Clin Transl Neurol. 2015;2(1):26-33. PMID: 25642424
  10. Grunseich C, Rinaldi C, Fischbeck KH. Spinal and bulbar muscular atrophy: pathogenesis and clinical management. Oral Dis. 2014;20(1):6-9. PMID: 23414145